[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1123811T1 - Κρυσταλλικη μορφη αναστολεα pde4 - Google Patents

Κρυσταλλικη μορφη αναστολεα pde4

Info

Publication number
CY1123811T1
CY1123811T1 CY20211100122T CY211100122T CY1123811T1 CY 1123811 T1 CY1123811 T1 CY 1123811T1 CY 20211100122 T CY20211100122 T CY 20211100122T CY 211100122 T CY211100122 T CY 211100122T CY 1123811 T1 CY1123811 T1 CY 1123811T1
Authority
CY
Cyprus
Prior art keywords
crystal form
pde4 inhibitor
inhibitor crystal
pde4
phosphodiesterase
Prior art date
Application number
CY20211100122T
Other languages
English (en)
Inventor
Alessandro Falchi
Emilio Lutero
Emanuele Ferrari
Fausto Pivetti
Rocco Bussolati
Edoardo Mariani
Orsola Vecchi
Erhard Bappert
Caterina Ventrici
Original Assignee
Chiesi Farmaceutici S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49385193&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123811(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farmaceutici S.P.A. filed Critical Chiesi Farmaceutici S.P.A.
Publication of CY1123811T1 publication Critical patent/CY1123811T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C205/59—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μια κρυσταλλική μορφή μιας ένωσης του τύπου (Ι) η οποία έχει ανασταλτική δραστικότητα φωσφοδιεστεράσης (PDE4) και σε φαρμακευτικές συνθέσεις για εισπνοή οι οποίες περιέχουν την εν λόγω μορφή σε συνδυασμό με κατάλληλους φορείς ή έκδοχα. Τέτοια προϊόντα είναι κατάλληλα για χρήση σε φαρμακευτικές εφαρμογές, για παράδειγμα, στη θεραπευτική αγωγή αναπνευστικών ασθενειών.
CY20211100122T 2013-10-22 2021-02-15 Κρυσταλλικη μορφη αναστολεα pde4 CY1123811T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13189784 2013-10-22
EP14795565.2A EP3060551B1 (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor
PCT/EP2014/072334 WO2015059050A1 (en) 2013-10-22 2014-10-17 Process for the preparation of a pde4 inhibitor

Publications (1)

Publication Number Publication Date
CY1123811T1 true CY1123811T1 (el) 2022-05-27

Family

ID=49385193

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100122T CY1123811T1 (el) 2013-10-22 2021-02-15 Κρυσταλλικη μορφη αναστολεα pde4

Country Status (30)

Country Link
US (7) US9434691B2 (el)
EP (5) EP3293176B1 (el)
JP (5) JP6458957B2 (el)
KR (3) KR102287598B1 (el)
CN (3) CN110256338A (el)
AR (4) AR098128A1 (el)
AU (1) AU2014339136C1 (el)
BR (1) BR112016008161B1 (el)
CA (3) CA3115570C (el)
CY (1) CY1123811T1 (el)
DK (3) DK3587400T3 (el)
ES (3) ES2857629T3 (el)
FI (1) FI3587400T3 (el)
HK (1) HK1223926A1 (el)
HR (3) HRP20240783T1 (el)
HU (2) HUE053112T2 (el)
IL (4) IL285532B2 (el)
LT (2) LT3293176T (el)
MX (4) MX370104B (el)
MY (1) MY182559A (el)
PH (2) PH12016500737B1 (el)
PL (3) PL3293176T3 (el)
PT (3) PT3587400T (el)
RS (2) RS61558B1 (el)
RU (1) RU2682660C9 (el)
SG (4) SG11201603130TA (el)
SI (3) SI3587400T1 (el)
TW (3) TWI720803B (el)
UA (2) UA121853C2 (el)
WO (1) WO2015059050A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171256A1 (es) 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
PT3587400T (pt) * 2013-10-22 2024-06-05 Chiesi Farm Spa Processo para a preparação de um inibidor de pde4
WO2018017713A1 (en) * 2016-07-20 2018-01-25 Allergan, Inc. Methods, compositions, and compounds for treatment of dermatological and ocular conditions
JP7361584B2 (ja) * 2018-12-19 2023-10-16 高砂香料工業株式会社 アミドの還元によるアミンの製造方法
JP6780763B2 (ja) 2018-12-25 2020-11-04 トヨタ自動車株式会社 内燃機関の制御装置
US11149615B2 (en) 2018-12-25 2021-10-19 Toyota Jidosha Kabushiki Kaisha Control device for internal combustion engine
CN111808029A (zh) * 2020-08-31 2020-10-23 兰晟生物医药(苏州)有限公司 一种pde4抑制剂氯比普兰的制备方法
WO2023117985A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023208982A1 (en) 2022-04-27 2023-11-02 Chiesi Farmaceutici S.P.A. Crystal form of a pde4 inhibitor
CN115304542B (zh) * 2022-07-18 2024-02-02 湖南华纳大药厂手性药物有限公司 一种3-羟基吡啶的合成工艺
WO2024027901A1 (en) 2022-08-02 2024-02-08 Chiesi Farmaceutici S.P.A. Predictive biomarker of clinical response to a pde4 inhibitor
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062005A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor
WO2024062006A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5935978A (en) * 1991-01-28 1999-08-10 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
DE60143842D1 (de) * 2000-03-30 2011-02-24 Chirotech Technology Ltd Ruthenium-diphosphin komplexe und ihre verwendung als katalysatoren
WO2005026095A1 (en) * 2003-09-12 2005-03-24 Ranbaxy Laboratories Limited Process for the preparation of roflumilast
US7999106B2 (en) 2004-04-19 2011-08-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Processes for the preparation of clopidogrel hydrogen sulfate polymorphic form I
JP4685861B2 (ja) * 2004-04-29 2011-05-18 アベンティス・ファーマスーティカルズ・インコーポレイテツド ドーパミンアゴニストとしての３−ピペリジニルイソクロマン−５−オール
KR20070079278A (ko) 2006-02-01 2007-08-06 삼성전자주식회사 수신자 제한 시스템을 이용하는 디지털 멀티미디어시스템에서 수신기의 채널 전환 시간 단축 장치 및 방법
ATE496029T1 (de) * 2006-07-14 2011-02-15 Chiesi Farma Spa Derivate von 1-phenyl-2-pyridinylalkylenalkohole als phosphodiesteraseinhibitoren
US8148537B2 (en) * 2006-12-22 2012-04-03 Leo Pharma A/S Substituted acetophenones useful as PDE4 inhibitors
EP2022783A1 (en) * 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
US20100015430A1 (en) 2008-07-16 2010-01-21 Outlast Technologies, Inc. Heat Regulating Article With Moisture Enhanced Temperature Control
EP2216327A1 (en) * 2009-02-06 2010-08-11 CHIESI FARMACEUTICI S.p.A. Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors
WO2011157387A1 (en) 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Crystal form of glycopyrronium chloride
PE20171256A1 (es) * 2010-08-03 2017-08-28 Chiesi Farm Spa Formulacion de polvo seco que comprende un inhibidor de fosfodiesterasa
EP3143987A1 (en) * 2010-08-03 2017-03-22 CHIESI FARMACEUTICI S.p.A. Pharmaceutical formulation comprising a phosphodiesterase inhibitor
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
WO2013045280A1 (en) * 2011-09-26 2013-04-04 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
AR089232A1 (es) * 2011-12-16 2014-08-06 Chiesi Farma Spa Potenciacion inducida por inhibidores de pde4 en el tratamiento de la leucemia
CN110698459B (zh) * 2012-12-05 2023-05-05 奇斯药制品公司 作为磷酸二酯酶抑制剂的1-苯基-2-吡啶基烷基醇衍生物
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
PT3587400T (pt) * 2013-10-22 2024-06-05 Chiesi Farm Spa Processo para a preparação de um inibidor de pde4
KR101591785B1 (ko) 2013-12-24 2016-02-04 주식회사 투게더 데이터 입력 장치, 이를 이용한 데이터 전송 시스템 및 방법
US20210038575A1 (en) * 2017-12-28 2021-02-11 Chiesi Farmaceutici S.P.A. Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
WO2023117985A1 (en) * 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity

Also Published As

Publication number Publication date
BR112016008161B1 (pt) 2022-11-29
CA3115570C (en) 2024-01-30
SI3587400T1 (sl) 2024-05-31
SG10201903575UA (en) 2019-05-30
SI3293176T1 (sl) 2021-04-30
US20190345108A1 (en) 2019-11-14
CN105658629B (zh) 2019-07-16
JP6458957B2 (ja) 2019-01-30
SI3060551T1 (sl) 2019-11-29
UA127453C2 (uk) 2023-08-30
WO2015059050A1 (en) 2015-04-30
UA121853C2 (uk) 2020-08-10
JP7534346B2 (ja) 2024-08-14
MX2022000030A (es) 2022-07-19
RU2682660C9 (ru) 2019-06-21
PT3587400T (pt) 2024-06-05
RS61558B1 (sr) 2021-04-29
MX2016004834A (es) 2016-07-19
HUE046637T2 (hu) 2020-03-30
MX370104B (es) 2019-12-02
ES2857629T3 (es) 2021-09-29
IL285528A (en) 2021-09-30
PH12020500162A1 (en) 2021-08-02
DK3060551T3 (da) 2019-10-28
JP2022071008A (ja) 2022-05-13
TW202021952A (zh) 2020-06-16
SG10201912852YA (en) 2020-02-27
SG11201603130TA (en) 2016-05-30
TWI651305B (zh) 2019-02-21
US11352327B2 (en) 2022-06-07
PL3587400T3 (pl) 2024-07-01
HRP20192152T1 (hr) 2020-02-21
MX2019014408A (es) 2020-01-27
DK3293176T3 (da) 2021-02-15
RU2682660C2 (ru) 2019-03-20
EP4059921A1 (en) 2022-09-21
EP3587400A2 (en) 2020-01-01
IL252834A0 (en) 2017-08-31
TW201904945A (zh) 2019-02-01
TWI720803B (zh) 2021-03-01
RS65452B1 (sr) 2024-05-31
EP3587400A3 (en) 2020-03-25
KR20160072127A (ko) 2016-06-22
US20160326117A1 (en) 2016-11-10
LT3293176T (lt) 2021-03-25
TW201605804A (zh) 2016-02-16
CN114621139A (zh) 2022-06-14
JP7345581B2 (ja) 2023-09-15
MY182559A (en) 2021-01-25
JP2022068321A (ja) 2022-05-09
SG10202112587RA (en) 2021-12-30
KR20210021416A (ko) 2021-02-25
JP2021011494A (ja) 2021-02-04
US20150111931A1 (en) 2015-04-23
AR122183A2 (es) 2022-08-24
JP2019038813A (ja) 2019-03-14
PH12016500737A1 (en) 2016-05-30
US10323003B2 (en) 2019-06-18
CN105658629A (zh) 2016-06-08
US10759761B2 (en) 2020-09-01
AU2014339136B2 (en) 2018-05-31
AR098128A1 (es) 2016-05-04
IL252834B (en) 2021-09-30
PT3293176T (pt) 2021-03-03
FI3587400T3 (fi) 2024-06-20
EP3798209A1 (en) 2021-03-31
EP3060551A1 (en) 2016-08-31
HRP20240783T1 (hr) 2024-09-27
IL285532B1 (en) 2023-11-01
EP3587400B1 (en) 2024-03-20
KR102287596B1 (ko) 2021-08-11
PL3060551T3 (pl) 2020-03-31
US9890122B2 (en) 2018-02-13
KR20210021415A (ko) 2021-02-25
CA3115587A1 (en) 2015-04-30
CA2928242C (en) 2022-03-15
HRP20210336T1 (hr) 2021-04-16
BR112016008161A2 (el) 2017-08-01
IL285532A (en) 2021-09-30
CA2928242A1 (en) 2015-04-30
US11981639B2 (en) 2024-05-14
EP3293176B1 (en) 2020-12-02
KR102240865B9 (ko) 2021-12-13
RU2016115246A (ru) 2017-11-27
ES2759514T3 (es) 2020-05-11
AU2014339136C1 (en) 2019-10-31
HK1223926A1 (zh) 2017-08-11
PL3293176T3 (pl) 2021-06-28
EP3293176A1 (en) 2018-03-14
US20180118686A1 (en) 2018-05-03
AR118124A2 (es) 2021-09-22
KR102240865B1 (ko) 2021-04-16
IL245220A0 (en) 2016-06-30
HUE053112T2 (hu) 2021-06-28
AR122182A2 (es) 2022-08-24
US9434691B2 (en) 2016-09-06
TWI685486B (zh) 2020-02-21
US20220348545A1 (en) 2022-11-03
LT3587400T (lt) 2024-04-25
CN110256338A (zh) 2019-09-20
DK3587400T3 (da) 2024-04-02
RU2016115246A3 (el) 2018-06-27
EP3060551B1 (en) 2019-09-18
KR102287598B1 (ko) 2021-08-11
ES2980505T3 (es) 2024-10-01
US20210040040A1 (en) 2021-02-11
JP7051970B2 (ja) 2022-04-11
IL245220A (en) 2017-06-29
PH12016500737B1 (en) 2016-05-30
PT3060551T (pt) 2019-12-09
US20240166605A1 (en) 2024-05-23
CA3115570A1 (en) 2015-04-30
IL285532B2 (en) 2024-03-01
MX2022000036A (es) 2022-07-19
JP2017505752A (ja) 2017-02-23

Similar Documents

Publication Publication Date Title
CY1123811T1 (el) Κρυσταλλικη μορφη αναστολεα pde4
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124476T1 (el) Egfr αναστολεας, και παρασκευη και εφαρμογη αυτου
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1124394T1 (el) Συνθεσεις τετραϋδροκινολινης ως αναστολεις βετ βρωμο-επικρατειων
CY1122707T1 (el) Ετεροκυκλικοι αναστολεις γλουταμινασης
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1125329T1 (el) Αντιιικες ενωσεις πυραζολο- και τριαζολο-πυριμιδινης εναντι toy rsv
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
CY1121360T1 (el) Αναστολεις dna-pk
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
EA201791576A1 (ru) Ингибитор jak
CY1123033T1 (el) Σπειροκυκλικοι αναστολεις της καθεψινης c
BR112017013491A2 (pt) compostos de pirimidina fundida para o tratamento de hiv
CY1119151T1 (el) Ν-(4-(αζαϊνδαζολ-6-υλ)-φαινυλ)-σουλφοναμιδiα και η χρηση τους ως φαρμακα
CY1119620T1 (el) Αναστολεις νεπριλυσινης
UY36285A (es) Compuestos que inhiben la proteína mcl-1
CR20150633A (es) Derivados del bipirazol como inhibidores jak
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
CY1120008T1 (el) Βενζαμιδια
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης